Juan Nogues - Pharma Mar Director Sales
0RC6 Stock | 75.72 2.97 4.08% |
Director
Juan Nogues is Director Sales of Pharma Mar SAU
Address | Avenida de los Reyes, 1, Madrid, Spain, 28770 |
Phone | 34 91 846 60 00 |
Web | https://www.pharmamar.com |
Pharma Mar Management Efficiency
At this time, Pharma Mar's Other Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 267.8 M in 2024, whereas Total Assets are likely to drop slightly above 276.5 M in 2024. Pharma Mar's management efficiency ratios could be used to measure how well Pharma Mar manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 9 records | DIRECTOR Age | ||
BE Eng | Associated British Foods | 52 | |
Rodrigo Maza | Naked Wines plc | 41 | |
Paul Emms | Bytes Technology | N/A | |
Andrew Holden | Bytes Technology | 57 | |
Thomas Hargreaves | Auction Technology Group | 54 | |
Tony Willis | Sabien Technology Group | N/A | |
Sam Mudd | Bytes Technology | 55 | |
Dominic Neary | Naked Wines plc | 48 | |
James Crawford | Naked Wines plc | 47 |
Management Performance
Return On Equity | 0.0032 | ||||
Return On Asset | -0.0065 |
Pharma Mar SAU Leadership Team
Elected by the shareholders, the Pharma Mar's board of directors comprises two types of representatives: Pharma Mar inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pharma. The board's role is to monitor Pharma Mar's management team and ensure that shareholders' interests are well served. Pharma Mar's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pharma Mar's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pedro Puentes, Executive ViceChairman | ||
Sandra Sanchez, Global Head | ||
Elena Crespo, Director Admin | ||
Jos MartinezLosa, Director Relations | ||
Juan Nogues, Director Sales | ||
Luis Cuenca, Director IT | ||
Luis Capitan, Managing Units | ||
Jose SousaFaro, Executive Founder | ||
Beln Veramendi, Director Development | ||
Mara Caballero, Chief Officer | ||
Juan Carretero, Founder | ||
Lara Vadillo, Communication Director | ||
Juan Pulido, General Directors |
Pharma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pharma Mar a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0032 | ||||
Return On Asset | -0.0065 | ||||
Profit Margin | 0 % | ||||
Operating Margin | 0.12 % | ||||
Current Valuation | 1.23 B | ||||
Shares Outstanding | 221.28 M | ||||
Shares Owned By Insiders | 21.39 % | ||||
Shares Owned By Institutions | 7.21 % | ||||
Price To Sales | 98.12 X | ||||
Revenue | 158.15 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pharma Stock Analysis
When running Pharma Mar's price analysis, check to measure Pharma Mar's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Mar is operating at the current time. Most of Pharma Mar's value examination focuses on studying past and present price action to predict the probability of Pharma Mar's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Mar's price. Additionally, you may evaluate how the addition of Pharma Mar to your portfolios can decrease your overall portfolio volatility.